# South America Plasma Fractionation Market > South America Plasma Fractionation Market Research Report: Size, Share, Trend Analysis By Product Type (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors), By Applications (Neurology, Hematology, General Medicine, Immunology), By End Users (Hospitals, Ambulatory Surgical Centers, Blood Banks, Pharmaceutical Companies), By Technology (Centrifugation, Chromatography, Precipitation, Filtration) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.59% - **2024:** $ 1,591 Million - **2025:** $ 1,695.85 Million - **2035:** $ 3,211 Million - **Key Players:** Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company (JP), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Sangamo Therapeutics (US) **Report ID:** MRFR/HC/47616-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-plasma-fractionation-market-49366 --- ## Market Summary ## **South America Plasma Fractionation Market Overview** As per MRFR analysis, the South America Plasma Fractionation Market Size was estimated at $2.27 billion in 2024. The South America Plasma Fractionation Market Industry is expected to grow from $2.84 billion in 2025 to $5.82 billion by 2035. The South America Plasma Fractionation Market CAGR (growth rate) is expected to be around 6.74% during the forecast period (2025 - 2035). ### **Key South America Plasma Fractionation Market Trends Highlighted** The South America Plasma Fractionation Market is witnessing notable trends driven by increasing demand for immunoglobulins and albumin, largely due to the rising prevalence of chronic diseases and the need for advanced therapeutic options. Countries like Brazil and Argentina are enhancing their healthcare infrastructure, which boosts the demand for plasma-derived products. The growing focus on biopharmaceuticals is also a significant market driver, as local governments support initiatives for innovation in biotechnology, indicating a shift towards developing domestic production capabilities to reduce reliance on imports. Opportunities in the South American plasma fractionation space are expanding, particularly as regional players invest in advanced technologies to improve the quality and efficiency of plasma collection and processing. This presents a unique chance for collaboration between private sectors and public health initiatives. Additionally, the ongoing regulatory reforms aimed at improving plasma donation safety can increase public confidence, thereby encouraging more people to donate, which is vital for the sustainability of plasma supply chains. Recent times have seen a shift in consumer attitudes, with greater awareness of the benefits of plasma-derived therapies fueling demand. Moreover, backup infrastructure to support the cold chain logistics for plasma products is being developed, enhancing distribution efficiency. There is also an emerging trend of partnerships between local firms and global players to facilitate knowledge transfer and technology exchange. This trend emphasizes the regional commitment to enhancing capabilities in plasma fractionation while ensuring that the increasing therapeutic needs of the population are met effectively and responsibly. Overall, the South America Plasma Fractionation Market is positioned for growth, driven by both demand and innovation in biotechnology. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South America Plasma Fractionation Market Drivers** ### **Increasing Demand for Immunoglobulin Therapies** The South America Plasma Fractionation Market is witnessing a growing demand for immunoglobulin therapies, which are derived from human plasma and used to treat various autoimmune and immunodeficiency disorders. According to data from the Brazilian Health Ministry, the incidence of primary immunodeficiency diseases in Brazil is estimated to be as high as 1 in 2,000 individuals. This translates to approximately 100,000 potential patients in Brazil alone who may benefit from immunoglobulin therapies. Additionally, organizations such as the Brazilian Society of Immunology are advocating for expanded access to these treatments, increasing awareness and demand in the region. The increased prevalence of conditions requiring immunoglobulin therapies is expected to significantly drive the South America Plasma Fractionation Market industry in the coming years. ### **Expansion of Healthcare Infrastructure** The improvement and expansion of healthcare infrastructure across South America are contributing to the growth of the South America Plasma Fractionation Market. For instance, the National Health Department of Argentina reported a 25% increase in the allocation of budget funds toward improving healthcare facilities and access to biopharmaceuticals in the past three years. This investment is enhancing the capacity for plasma collection and processing, leading to higher production capabilities for plasma-derived products. The improvement of healthcare facilities enables the industry to optimize the growing need for efficient and safe plasma therapies, thus helping the industry grow. ### **Rising Awareness and Acceptance of Plasma Therapies** There has been a significant increase in awareness and acceptance of plasma therapies among both healthcare professionals and patients in South America. A recent survey conducted by the Argentine Blood Transfusion Foundation revealed that approximately 65% of healthcare providers now recognize the therapeutic benefits of plasma-derived therapies. As a result, patients are increasingly seeking these treatments, leading to a more substantial demand for products derived from plasma fractionation. This growing awareness and acceptance are critical drivers for the growth of the South America Plasma Fractionation Market, as they encourage healthcare systems to invest more in these therapies. ## **South America Plasma Fractionation Market Segment Insights** ### **Plasma Fractionation Market Product Type Insights** The South America Plasma Fractionation Market is diverse and includes various product types that cater to a range of medical needs. Among these product types, Immunoglobulin emerges as a significant segment, primarily used in treating immune deficiencies, autoimmune diseases, and inflammatory conditions, reflecting its indispensable role in therapeutic therapies. Albumin is another vital component derived from plasma, extensively utilized for various health issues, including carrying medications and fluids in the bloodstream, which indicates its pivotal role in patient care and recovery settings. Moreover, Coagulation Factors hold crucial importance in treating hemophilia and other bleeding disorders, underscoring the need for advanced treatments in the region, while Protease Inhibitors, though a smaller segment, are gaining attention for their potential role in treating various conditions, including certain viral infections. The growing awareness of blood-related disorders and the rise in healthcare services across South America drives the demand for these product types. As the healthcare industry in the region evolves, providers are expected to leverage advances in plasma fractionation technology, significantly enhancing production efficacy and ensuring patient safety and care. Each of these product types plays a crucial role not only in treatment but also reflects the expanding healthcare infrastructure needed to meet the rising demand for plasma-derived therapies in South America. The South America Plasma Fractionation Market segmentation highlights the importance of immunological research and innovation in producing effective therapies, shaping the overall industry's growth trajectory as science progresses. The increasing investment into healthcare initiatives further underscores the opportunities within this market, aiming to provide high-quality therapies that meet patient needs while enhancing health outcomes across the region. The insights into these segments showcase a market that is robust, diverse, and inspired by the need for advanced therapeutic solutions and improved health services. Overall, understanding the dynamics of each product type is critical for stakeholders aiming to navigate the evolving landscape of the South America Plasma Fractionation Market as they seek to align with health trends and patient requirements in this increasingly important sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Plasma Fractionation Market Application Insights** The South America [Plasma Fractionation Market](../../../reports/plasma-fractionation-market-7397) is notably segmented into various applications, including Neurology, Hematology, General Medicine, and Immunology, each contributing to the region's healthcare development. Neurology is crucial due to the increasing prevalence of neurological disorders, providing essential therapies derived from plasma. In Hematology, plasma-derived immunoglobulins serve significant roles in treating blood conditions, reflecting the growing demand for blood products. General Medicine encompasses a diverse range of treatments, reinforcing the importance of plasma fractionation in overall healthcare. Immunology continues to dominate as advancements in disease management and immunotherapies rise, reflecting significant growth within this sector. Collectively, these applications highlight the critical role of plasma fractionation in addressing prevalent health needs in South America, indicating a robust growth trajectory moving forward as healthcare facilities expand and technologies improve. Furthermore, regional initiatives aimed at enhancing healthcare accessibility and developing advanced medical facilities contribute to the South America Plasma Fractionation Market's momentum, ensuring the continuous support of diverse therapeutic areas. ### **Plasma Fractionation Market End User Insights** The South America Plasma Fractionation Market shows significant activity in the End User segment, which encompasses various critical sectors such as Hospitals, Ambulatory Surgical Centers, Blood Banks, and Pharmaceutical Companies. Hospitals represent a substantial portion of this market due to their extensive need for plasma-derived products in treatments and therapies for various ailments. Ambulatory Surgical Centers are increasingly gaining traction as they offer efficient and cost-effective healthcare solutions, further driving demand for plasma fractionation. Blood Banks play a crucial role in the collection and processing of plasma, serving as a vital source of therapeutic proteins, which are essential for patients with clotting disorders. Meanwhile, Pharmaceutical Companies significantly contribute to the market, leveraging advanced technologies in R&D to develop innovative plasma-based therapies. The growing prevalence of chronic diseases in South America, combined with the rising healthcare expenditure, presents numerous opportunities for expansion across these segments. Furthermore, the increasing awareness of the benefits of plasma products among healthcare providers and patients alike is driving market growth, underscoring the importance of each sector in meeting the region’s healthcare demands. ### **Plasma Fractionation Market Technology Insights** The South America Plasma Fractionation Market is witnessing significant growth driven by advancements in technology. The Technology segment encompasses various processes essential for the separation and purification of plasma proteins. Centrifugation remains crucial as it efficiently separates components based on density, making it vital for producing various therapeutic products. Chromatography is also important since it enables high-resolution separation, thereby enhancing product quality and efficacy, appealing to pharmaceutical companies focused on precision medicine. Precipitation methods are recognized for their cost-effectiveness and simplicity in isolating proteins, appealing to emerging biotech firms in South America. Filtration techniques, notably membrane filtration, ensure high purity by removing contaminants, aligning with stringent regulatory standards in the healthcare industry. The South America Plasma Fractionation Market is supported by increasing investments in healthcare infrastructure and a growing emphasis on biotechnology, advancing these technologies. However, challenges like high operational costs and complex regulatory environments may require strategic innovation and collaboration, providing opportunities for growth and improvement in the efficiency of plasma fractionation processes. Overall, the demarcation of Technology in the plasma fractionation landscape illustrates a robust movement towards enhancing therapeutic capabilities and meeting the region's healthcare needs. ### **Plasma Fractionation Market Regional Insights** The South America Plasma Fractionation Market is witnessing notable growth, driven by increasing healthcare expenditure and advancements in biotechnology. Within the region, Brazil stands out as a dominant player, contributing significantly to market developments due to its large population and advanced medical infrastructure. Mexico also plays a crucial role, with growing investments in biopharmaceuticals and increasing awareness of plasma-derived therapies driving demand. Argentina's emerging healthcare sector presents new opportunities, particularly as the country enhances its biomanufacturing capabilities. The Rest of South America segment showcases potential growth, reflecting innovations in healthcare access and increasing investments in research and development. The efficient management of plasma resources and government initiatives to improve healthcare quality further stimulate the market. Overall, the South America Plasma Fractionation Market segmentation highlights diverse opportunities across the region, each contributing to a robust growth trajectory influenced by regional needs and healthcare advancements. **Source: Primary Research, Secondary Research, MRFR Database and Analyst Review** ## **South America Plasma Fractionation Market Key Players and Competitive Insights** The South America Plasma Fractionation Market has been evolving rapidly in recent years, propelled by increasing demand for immunoglobulins, clotting factors, and other derived therapeutics. The competitive landscape is characterized by a diverse set of players ranging from multinational corporations to specialized regional firms. Factors such as advanced technology integration, rising awareness regarding the therapeutic applications of plasma-derived products, and supportive government initiatives aimed at enhancing healthcare infrastructure are contributing to the dynamic nature of this market. Companies are engaged in strategic collaborations, partnerships, and innovation to enhance their market position and address the growing healthcare needs of the region. As the market matures, competition is intensifying, with companies constantly striving to maintain their edge through product development and operational efficiency. Octapharma holds a prominent position in the South America Plasma Fractionation Market, with a strong focus on producing high-quality plasma-derived products. The company has established significant market presence due to its extensive product range, including human plasma-derived immunoglobulins and coagulation factor concentrates, addressing various health challenges in the region. Octapharma’s ability to leverage state-of-the-art technology in its fractionation processes enables it to maintain high standards of product quality and safety. Furthermore, the firm’s significant investment in research and development enhances its capacity to innovate and respond to the evolving therapeutic demands within the South American healthcare landscape. The company's strong distribution network and established relationships with healthcare providers have further solidified its standing, allowing it to effectively cater to the unique needs of the local market. ImmunoPrecise Antibodies has carved a niche for itself in the South America Plasma Fractionation Market with a focus on monoclonal antibodies and custom antibody development services. The company’s expertise in providing specialized diagnostics and therapeutic solutions has positioned it favorably in this competitive landscape. ImmunoPrecise Antibodies is recognized for its ability to leverage cutting-edge technologies and advanced methodologies in the production of antibody-based therapies, which meet the specific requirements of the healthcare sector in South America. The company's commitment to collaboration has led to strategic partnerships and mergers that bolster its market presence, enhancing research capabilities and broadening its service offerings. This focused approach not only strengthens ImmunoPrecise Antibodies’ role in the region but also underscores its potential to contribute significantly to the advancement of plasma-derived therapies tailored to the needs of South American patients. ### Key Companies in the South America Plasma Fractionation Market Include - **[Octapharma](https://www.octapharma.com/products/production-process)** - ImmunoPrecise Antibodies - Biotest AG - Grifols - Prothera - Takeda Pharmaceutical - Sangamo Therapeutics - CSL Behring - Shire - LFB - Hematologic Technologies - Hyaluronic Acid - Fractionation Technologies - Kedrion Biopharma ### **South America Plasma Fractionation Market Industry Developments** The South America Plasma Fractionation Market has seen significant developments recently, particularly in the growth and expansion of major companies like Grifols and Takeda Pharmaceutical. In September 2023, Grifols announced the opening of a new plasma collection center in Brazil, further solidifying its presence in the region. Meanwhile, Takeda Pharmaceutical has been actively investing in enhancing its plasma-derived therapies in South America to meet increasing local demand, indicative of a promising market environment. In terms of mergers and acquisitions, ImmunoPrecise Antibodies was involved in a notable acquisition in July 2023, adding valuable product lines that align with the company’s strategic goals in plasma-derived products. The market has also witnessed an increase in investments from CSL Behring, who aims to establish more facilities to enhance local production capabilities. The steady growth of the South America plasma fractionation market can be attributed to an uptick in healthcare spending and advancements in processing technologies, promoting innovations among key players like Octapharma and Biotest AG as they adapt to the evolving market dynamics. This landscape facilitates increased access to vital therapies across the region, catering to both current and future healthcare needs. ## **South America Plasma Fractionation Market Segmentation Insights** ### **Plasma Fractionation Market Product Type Outlook** - Immunoglobulin - Albumin - Coagulation Factors - Protease Inhibitors ### **Plasma Fractionation Market Application Outlook** - Neurology - Hematology - General Medicine - Immunology ### **Plasma Fractionation Market End User Outlook** - Hospitals - Ambulatory Surgical Centers - Blood Banks - Pharmaceutical Companies ### **Plasma Fractionation Market Technology Outlook** - Centrifugation - Chromatography - Precipitation - Filtration ### **Plasma Fractionation Market Regional Outlook** - Brazil - Mexico - Argentina - Rest of South America ## Market Drivers ### Supportive Government Policies Supportive government policies in South America are fostering a conducive environment for the plasma fractionation market. Regulatory frameworks are being established to streamline the approval processes for plasma-derived therapies, ensuring that they reach the market more efficiently. Additionally, governments are incentivizing research and development in this field, which could lead to innovative products and therapies. As a result, the plasma fractionation market is likely to experience accelerated growth, with projections indicating a potential increase in market size by 8% over the next five years. This supportive landscape is essential for attracting investments and enhancing the overall market dynamics. ### Increasing Healthcare Expenditure The rising healthcare expenditure in South America is a pivotal driver for the plasma fractionation market. Governments and private sectors are investing more in healthcare infrastructure, which includes the procurement of advanced medical technologies. In 2025, healthcare spending in South America is projected to reach approximately $500 billion, reflecting a growth rate of around 5% annually. This increase in funding allows for better access to plasma-derived therapies, thereby enhancing the demand for immunoglobulins and other plasma products. As healthcare systems evolve, the plasma fractionation market is likely to benefit from improved facilities and increased patient access to essential treatments, which could further stimulate market growth. ### Growing Prevalence of Chronic Diseases The prevalence of chronic diseases in South America is escalating, which significantly impacts the plasma fractionation market. Conditions such as autoimmune disorders, hemophilia, and other blood-related diseases are becoming more common, necessitating the use of plasma-derived therapies. Reports indicate that chronic diseases account for nearly 60% of all deaths in the region, highlighting the urgent need for effective treatment options. This growing patient population is likely to drive demand for immunoglobulins and clotting factors, thereby propelling the plasma fractionation market. As healthcare providers seek to address these challenges, the industry is expected to expand to meet the increasing therapeutic needs. ### Advancements in Plasma Collection Techniques Innovations in plasma collection techniques are emerging as a crucial driver for the plasma fractionation market in South America. Enhanced methods for plasma collection, such as automated apheresis, are improving the efficiency and safety of the process. These advancements not only increase the yield of plasma but also ensure better quality, which is essential for producing high-quality plasma-derived products. As a result, the market is likely to see a rise in the availability of immunoglobulins and clotting factors, meeting the growing demand from healthcare providers. The ongoing development of these technologies could potentially lead to a market growth rate of 6% over the next few years. ### Rising Awareness of Plasma-Derived Therapies There is a notable increase in awareness regarding the benefits of plasma-derived therapies among healthcare professionals and patients in South America. Educational initiatives and outreach programs are being implemented to inform stakeholders about the efficacy of these treatments for various medical conditions. This heightened awareness is likely to lead to increased prescriptions and utilization of plasma products, thereby driving growth in the plasma fractionation market. As more patients become informed about their treatment options, the demand for immunoglobulins and other plasma-derived therapies is expected to rise, potentially leading to a market expansion of around 7% annually. ## Future Outlook The [Plasma Fractionation Market](https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397) is projected to grow at 6.59% CAGR from 2025 to 2035, driven by increasing demand for immunoglobulins and advancements in fractionation technologies. **New opportunities:** - Expansion of contract manufacturing services for biopharmaceutical companies. - Development of innovative plasma-derived therapies targeting rare diseases. - Investment in automated plasma collection and processing technologies. By 2035, the plasma fractionation market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Neurology (Largest) vs. Immunology (Fastest-Growing) In the South America plasma fractionation market, Neurology holds the largest share due to the increasing prevalence of neurological disorders and the rising demand for innovative therapies. Hematology and General Medicine also contribute significantly, but their market shares are comparatively smaller. Additionally, the Immunology sector is gaining traction as more therapies for autoimmune diseases and related conditions are developed, impacting share distribution. Growth trends in this segment are fueled by several factors including technological advancements in plasma fractionation processes and an increase in research activities targeting various diseases. Moreover, the rise in healthcare expenditure and awareness regarding plasma-derived therapies are expected to propel the demand for all applications, particularly in Immunology which is emerging rapidly due to novel drug developments. Neurology: Dominant vs. Immunology: Emerging Neurology is currently the dominant application in the South America plasma fractionation market, largely due to a strong focus on treating chronic neurological conditions such as multiple sclerosis and hemophilia with plasma-derived therapies. This segment benefits from robust infrastructure and established protocols making it the preferred choice among healthcare providers. On the other hand, Immunology is emerging as a pivotal area, driven by increased research and innovation, especially in therapies addressing autoimmune diseases. As pharmaceutical companies invest heavily in this area, the growth potential for Immunology apps widens, signaling an essential shift in market dynamics where emerging segments like Immunology could challenge the dominance of established ones like Neurology in the near future. ### By Product Type: Immunoglobulin (Largest) vs. Albumin (Fastest-Growing) The market share distribution among product types reveals that Immunoglobulin holds a significant proportion of the total market, largely due to its critical role in treating various immune deficiencies. Albumin is gaining traction, demonstrating strong growth patterns as it is increasingly utilized in therapeutic applications, making it an attractive segment for future investments. Current growth trends indicate a robust demand for both Immunoglobulin and Albumin, driven by rising incidences of chronic diseases and an aging population in South America. The increasing awareness regarding the therapeutic benefits and diverse applications of these products further propels their market acceptance and expansion. Factors such as advancements in manufacturing processes and regulatory approvals also contribute to their growth trajectories in this competitive market. Immunoglobulin: Dominant vs. Albumin: Emerging Immunoglobulin remains a dominant product type in the South America plasma fractionation market, characterized by its extensive clinical applications in immunotherapy and infectious disease treatment. This segment benefits from established manufacturing processes and a strong supply chain. In contrast, Albumin is emerging as a rapidly growing segment, known for its versatility in treating various medical conditions like liver disorders and trauma cases. Albumin's demand is on the rise due to its effectiveness as a plasma volume expander and its increasing use in surgical and critical care settings. The evolving healthcare landscape fosters a competitive environment where both product types are pivotal in addressing patient needs. ### By End User: Hospitals (Largest) vs. Blood Banks (Fastest-Growing) In the South America plasma fractionation market, Hospitals hold the largest market share, benefiting from the ever-increasing demand for plasma-based products in patient care. Blood Banks, while smaller in market share compared to hospitals, are witnessing significant growth, driven by the rising need for blood transfusions and blood-derived therapies. Ambulatory Surgical Centers and Pharmaceutical Companies also contribute to the market but are comparatively smaller segments within this landscape. The growth trends within this segment are notably influenced by various factors, including the increasing prevalence of chronic diseases that require plasma-derived therapies and advancements in medical technology that improve processing capabilities. The commitment to enhancing healthcare infrastructure and the growing awareness of the benefits of plasma therapies further fuel the expansion of both Hospitals and Blood Banks, making them pivotal players in the evolving market dynamics. Hospitals (Dominant) vs. Pharmaceutical Companies (Emerging) Hospitals are regarded as the dominant end-user in the plasma fractionation landscape, primarily due to their extensive utilization of plasma products for various therapeutic and surgical procedures. Their significant role is complemented by a robust integration of advanced facilities and trained personnel to manage plasma resources efficiently. In contrast, Pharmaceutical Companies represent an emerging segment, focusing on the development and manufacture of innovative therapies derived from plasma. They are increasingly investing in research and development to create novel treatments that leverage human plasma, enhancing their market presence and driving growth alongside the established hospital sector. ### By Technology: Centrifugation (Largest) vs. Chromatography (Fastest-Growing) In South America, the segment distribution for plasma fractionation highlights that centrifugation holds the largest market share due to its efficiency and established technology in separating plasma components. This method continues to dominate the landscape, while chromatography emerges as a strong contender, gaining traction and increasing its share among emerging players and innovative applications in therapeutic development. The growth trends within this segment are driven by advancements in technology and the demand for high-purity plasma-derived products. The increasing prevalence of blood-related disorders and the corresponding rise in demand for immunoglobulins and clotting factors are propelling developments in chromatography. As companies invest in research and development, chromatography is expected to outpace other methods in terms of growth rate, appealing to manufacturers aiming for quality and efficiency. Centrifugation (Dominant) vs. Chromatography (Emerging) Centrifugation remains the dominant technology in the South America plasma fractionation market, characterized by its reliability and high throughput in separating cellular components from plasma. This technique leverages centrifugal force to effectively partition the plasma constituents based on their density, making it essential in various applications. On the other hand, chromatography is an emerging technique gaining ground rapidly due to its ability to achieve higher purity levels and specificity in separating complex mixtures. Its versatility in the preparation of therapeutic proteins and biologics is a significant advantage, attracting increasing investment and technological advancements aimed at improving efficiency and scalability. ## Regional Market Share Analysis ### Brazil : Strong Demand and Infrastructure Growth Brazil holds a dominant position in the South American plasma fractionation market, accounting for approximately 53.1% of the total market share with a value of $750.0 million. Key growth drivers include increasing healthcare expenditure, rising awareness of plasma-derived therapies, and supportive government policies aimed at enhancing healthcare infrastructure. The Brazilian government has implemented initiatives to promote local production and reduce dependency on imports, fostering a favorable regulatory environment for market expansion. ### Mexico : Growing Demand and Investment Opportunities Mexico represents a significant portion of the South American plasma fractionation market, with a value of $300.0 million, accounting for 20.8% of the market share. The growth is driven by increasing healthcare investments, a rising prevalence of chronic diseases, and a growing population. Regulatory frameworks are evolving to support the plasma industry, with initiatives aimed at improving collection and processing facilities, which are crucial for meeting rising demand. ### Argentina : Focus on Local Production and Innovation Argentina's plasma fractionation market is valued at $400.0 million, representing 28.2% of the market share in South America. The sector is experiencing steady growth due to increased local production capabilities and government support for biotechnology initiatives. Demand for immunoglobulins and clotting factors is rising, driven by a growing patient population and advancements in medical technology. Regulatory bodies are working to streamline processes, enhancing the business environment for local players. ### Rest of South America : Diverse Opportunities Across Borders The Rest of South America accounts for a smaller segment of the plasma fractionation market, valued at $141.0 million, or 10.0% of the total market share. This sub-region presents niche opportunities driven by varying healthcare needs and regulatory environments. Countries like Chile and Colombia are investing in healthcare infrastructure, which is expected to boost plasma collection and processing capabilities. Local players are emerging, but competition remains limited compared to larger markets like Brazil and Argentina. ## Competitive Benchmarking The plasma fractionation market in South America is characterized by a dynamic competitive landscape, driven by increasing demand for immunoglobulins and clotting factors. Key players are actively pursuing strategies that emphasize innovation, regional expansion, and strategic partnerships. Companies such as Grifols (ES), CSL Behring (AU), and Takeda Pharmaceutical Company (JP) are at the forefront, leveraging their extensive product portfolios and established market presence to enhance their competitive positioning. Grifols, for instance, focuses on expanding its manufacturing capabilities and enhancing its product offerings, which appears to strengthen its market share in the region. In terms of business tactics, localizing manufacturing and optimizing supply chains are critical for success in this market. The competitive structure is moderately fragmented, with several players vying for market share. However, the influence of major companies like CSL Behring and Takeda Pharmaceutical Company is substantial, as they continue to innovate and adapt to the evolving market demands. Their collective strategies not only shape the competitive environment but also set benchmarks for operational excellence. In October 2025, CSL Behring (AU) announced a strategic partnership with a local biotechnology firm to enhance its research capabilities in plasma-derived therapies. This collaboration is expected to accelerate the development of new treatments, thereby reinforcing CSL Behring's commitment to innovation and responsiveness to regional healthcare needs. Such partnerships may also facilitate access to local expertise and resources, which could be pivotal in navigating regulatory landscapes. In September 2025, Takeda Pharmaceutical Company (JP) unveiled plans to invest $150 million in expanding its plasma collection facilities in Brazil. This investment is likely to bolster Takeda's supply chain resilience and ensure a steady supply of high-quality plasma for fractionation. By enhancing its operational footprint in South America, Takeda appears to be positioning itself as a key player in meeting the growing demand for plasma-derived products in the region. In August 2025, Grifols (ES) launched a new line of immunoglobulin products specifically tailored for the South American market. This strategic move not only diversifies Grifols' product offerings but also demonstrates its commitment to addressing local healthcare challenges. The introduction of these products may enhance patient access to essential therapies, thereby solidifying Grifols' reputation as a leader in the plasma fractionation sector. As of November 2025, current trends in the plasma fractionation market include a pronounced shift towards digitalization and sustainability. Companies are increasingly integrating advanced technologies, such as AI, to optimize production processes and enhance product quality. Strategic alliances are becoming more prevalent, as firms recognize the value of collaboration in driving innovation and improving supply chain reliability. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements and sustainable practices, underscoring the importance of innovation in maintaining market leadership. ## Recent News & Developments The South America Plasma Fractionation Market has seen significant developments recently, particularly in the growth and expansion of major companies like Grifols and Takeda Pharmaceutical. In September 2023, Grifols announced the opening of a new plasma collection center in Brazil, further solidifying its presence in the region. Meanwhile, Takeda Pharmaceutical has been actively investing in enhancing its plasma-derived therapies in South America to meet increasing local demand, indicative of a promising market environment. In terms of mergers and acquisitions, ImmunoPrecise Antibodies was involved in a notable acquisition in July 2023, adding valuable product lines that align with the company’s strategic goals in plasma-derived products. The market has also witnessed an increase in investments from CSL Behring, who aims to establish more facilities to enhance local production capabilities. The steady growth of the South America plasma fractionation market can be attributed to an uptick in healthcare spending and advancements in processing technologies, promoting innovations among key players like Octapharma and Biotest AG as they adapt to the evolving market dynamics. This landscape facilitates increased access to vital therapies across the region, catering to both current and future healthcare needs. ## Report Scope | MARKET SIZE 2024 | 1591.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1695.85(USD Million) | | MARKET SIZE 2035 | 3211.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.59% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company (JP), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Sangamo Therapeutics (US) | | Segments Covered | Application, Product Type, End User, Technology | | Key Market Opportunities | Emerging technologies in plasma fractionation enhance efficiency and expand therapeutic applications in South America. | | Key Market Dynamics | Rising demand for immunoglobulins drives innovation and competition in the plasma fractionation market. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What is the projected market valuation for the South America plasma fractionation market in 2035?** A: The projected market valuation for the South America plasma fractionation market in 2035 is expected to reach $3211.0 Million. **Q: What was the market valuation for the South America plasma fractionation market in 2024?** A: The market valuation for the South America plasma fractionation market in 2024 was $1591.0 Million. **Q: What is the expected CAGR for the South America plasma fractionation market during the forecast period 2025 - 2035?** A: The expected CAGR for the South America plasma fractionation market during the forecast period 2025 - 2035 is 6.59%. **Q: Which companies are considered key players in the South America plasma fractionation market?** A: Key players in the South America plasma fractionation market include Grifols, CSL Behring, Takeda Pharmaceutical Company, Octapharma, Kedrion, Biotest AG, LFB Group, and Sangamo Therapeutics. **Q: What are the main application segments in the South America plasma fractionation market?** A: The main application segments in the South America plasma fractionation market include Neurology, Hematology, General Medicine, and Immunology. **Q: What is the valuation range for the Immunology segment in the South America plasma fractionation market?** A: The valuation range for the Immunology segment in the South America plasma fractionation market is $636.4 Million to $1290.0 Million. **Q: How does the valuation of the General Medicine segment compare to the Hematology segment?** A: The valuation of the General Medicine segment ranges from $477.3 Million to $960.0 Million, whereas the Hematology segment ranges from $318.2 Million to $640.0 Million. **Q: What are the key product types in the South America plasma fractionation market?** A: Key product types in the South America plasma fractionation market include Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors. **Q: What is the expected valuation for the Hospitals end-user segment by 2035?** A: The expected valuation for the Hospitals end-user segment by 2035 is projected to be between $600.0 Million and $1200.0 Million. **Q: What technologies are utilized in the South America plasma fractionation market?** A: Technologies utilized in the South America plasma fractionation market include Centrifugation, Chromatography, Precipitation, and Filtration. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-plasma-fractionation-market-49366*